MICHAEL TREISMAN: Open Payments
NPI 1184685455 · FLORISSANT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$760 in 40 payments from 13 companies in 2025. Trend: 2023 $779 · 2024 $696 · 2025 $760
Food & beverage: $760
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $220 |
| AstraZeneca Pharmaceuticals LP | 4 | $143 |
| GlaxoSmithKline, LLC. | 5 | $88 |
| Lilly USA, LLC | 3 | $58 |
| Novo Nordisk Inc | 3 | $56 |
| Amgen Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $32 |
| Medtronic, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: FARXIGA, QULIPTA, TRELEGY ELLIPTA, UBRELVY, AIRSUPRA, VRAYLAR, EVENITY, MOUNJARO.
Industry payments across MO — which companies pay providers there.
